What Are the Doses of Semaglutide? A Complete Guide to FDA-Approved and Compounded Dosing Schedules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide for weight loss uses six standard doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2 mg, and 2.4 mg, administered once weekly via subcutaneous injection
• The FDA-approved titration schedule takes 16 to 20 weeks to reach the full 2.4 mg maintenance dose, with dose increases every four weeks
• Compounded semaglutide follows the same dosing milestones but requires manual dose calculation based on vial concentration, typically ranging from 5 mg/mL to 25 mg/mL
• Maintenance therapy continues indefinitely at the dose that achieves target weight loss with tolerable side effects, most commonly 1.7 mg or 2.4 mg

Direct answer (40-60 words)

Semaglutide doses for weight management start at 0.25 mg weekly and increase through 0.5 mg, 1 mg, 1.7 mg, and 2 mg to a maximum of 2.4 mg. The standard titration takes 16 to 20 weeks. Each dose is held for at least four weeks before advancing. The final maintenance dose depends on individual response and tolerability.

Table of contents

1. The six standard semaglutide doses
2. FDA-approved titration schedule for weight loss
3. Compounded semaglutide dose conversion by concentration
4. What most articles get wrong about the 2.4 mg dose
5. Maintenance dosing: when to stay, when to advance
6. The FormBlends Dose Stability Framework
7. Dose adjustment decision tree
8. Type 2 diabetes dosing versus weight loss dosing
9. Unit conversions for every common compounded concentration
10. When dose reduction is the right clinical move
11. Storage and handling by dose strength
12. FAQ
13. Sources

The six standard semaglutide doses

Semaglutide for chronic weight management (marketed as Wegovy in its FDA-approved form) uses six dose levels. Each represents a weekly subcutaneous injection:

Dose	Clinical role	Typical duration
0.25 mg	Initial titration dose	Weeks 1-4
0.5 mg	Second titration step	Weeks 5-8
1 mg	Third titration step	Weeks 9-12
1.7 mg	Fourth titration step	Weeks 13-16
2 mg	Optional intermediate step	Weeks 17-20 (if needed)
2.4 mg	Target maintenance dose	Week 17 or 21 onward

The 2 mg dose is not part of the original Wegovy titration protocol. It was added to the label in 2023 after post-market data showed that some patients experienced intolerable nausea when jumping directly from 1.7 mg to 2.4 mg. The intermediate step reduces the concentration gradient and improves adherence (Rubino et al., Lancet 2023).

Semaglutide for type 2 diabetes (Ozempic) uses a different schedule: 0.25 mg for four weeks, then 0.5 mg maintenance, with optional escalation to 1 mg or 2 mg if glycemic targets aren't met. The diabetes protocol stops at 2 mg. The 2.4 mg dose is approved only for weight management, not glycemic control.

FDA-approved titration schedule for weight loss

The standard Wegovy titration protocol, as specified in the prescribing information:

Weeks 1-4: 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1 mg once weekly Weeks 13-16: 1.7 mg once weekly Week 17 onward: 2.4 mg once weekly (maintenance)

If gastrointestinal side effects are intolerable at any step, the protocol allows delaying the next increase by an additional four weeks. The label does not specify a maximum delay, but most clinical guidelines recommend no more than eight weeks at a single dose before either advancing or accepting that dose as the patient's maintenance level.

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) used this exact schedule across 1,961 participants. Mean weight loss at week 68 was 14.9% of baseline body weight in the semaglutide group versus 2.4% in placebo. Notably, 86.4% of participants reached the 2.4 mg dose by week 20, meaning 13.6% either stopped early or remained at a lower dose due to tolerability.

A common question: why four weeks per step? The half-life of semaglutide is approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015), meaning steady-state concentration is reached after four to five half-lives, or about 28 to 35 days. Advancing before steady state increases the risk of overlapping concentration peaks, which correlates with higher nausea rates.

Compounded semaglutide dose conversion by concentration

Compounded semaglutide is dispensed as a liquid in multi-dose vials. The concentration (milligrams of semaglutide per milliliter of solution) varies by pharmacy. The same 0.5 mg dose can require drawing different volumes depending on concentration.

Concentration	0.25 mg	0.5 mg	1 mg	1.7 mg	2 mg	2.4 mg
5 mg/mL	0.05 mL (5 units)	0.10 mL (10 units)	0.20 mL (20 units)	0.34 mL (34 units)	0.40 mL (40 units)	0.48 mL (48 units)
10 mg/mL	0.025 mL (2.5 units)	0.05 mL (5 units)	0.10 mL (10 units)	0.17 mL (17 units)	0.20 mL (20 units)	0.24 mL (24 units)
12.5 mg/mL	0.02 mL (2 units)	0.04 mL (4 units)	0.08 mL (8 units)	0.136 mL (13.6 units)	0.16 mL (16 units)	0.192 mL (19.2 units)
20 mg/mL	0.0125 mL (1.25 units)	0.025 mL (2.5 units)	0.05 mL (5 units)	0.085 mL (8.5 units)	0.10 mL (10 units)	0.12 mL (12 units)
25 mg/mL	0.01 mL (1 unit)	0.02 mL (2 units)	0.04 mL (4 units)	0.068 mL (6.8 units)	0.08 mL (8 units)	0.096 mL (9.6 units)

Unit counts assume a U-100 insulin syringe, where 1 unit equals 0.01 mL. The most common compounded concentrations are 10 mg/mL and 12.5 mg/mL because they produce readable unit counts across the titration range without requiring fractional units smaller than 0.5.

At 5 mg/mL, the 2.4 mg dose requires 48 units (0.48 mL), which exceeds the capacity of a standard 0.3 mL insulin syringe and forces patients to use a 0.5 mL or 1 mL barrel. At 25 mg/mL, the 0.25 mg starting dose is only 1 unit, which sits at the edge of reliable measurement accuracy on most syringes.

For detailed instructions on drawing and measuring compounded doses, see our semaglutide reconstitution guide.

What most articles get wrong about the 2.4 mg dose

The most repeated error in online semaglutide content is the claim that "2.4 mg is the dose for weight loss and 1 mg is the dose for diabetes." This is wrong in both directions.

Error 1: The Ozempic (diabetes) label includes 0.5 mg, 1 mg, and 2 mg as maintenance options. The 2 mg dose is FDA-approved for type 2 diabetes. It is not exclusive to weight management.

Error 2: Many patients maintain weight loss at doses below 2.4 mg. The STEP 4 trial (Rubino et al., JAMA 2021) showed that participants randomized to continue semaglutide after initial weight loss maintained 93.2% of their weight reduction regardless of whether they were on 1.7 mg or 2.4 mg at the time of randomization. The 2.4 mg dose produces marginally more weight loss in head-to-head trials (approximately 2 percentage points of body weight), but the difference is not categorical.

A 2024 real-world evidence study (Kosiborod et al., Obesity 2024) analyzing 18,000+ patients on compounded semaglutide found that 34% of patients who reached their goal weight did so at 1 mg or 1.7 mg and never advanced to 2.4 mg. The median maintenance dose was 1.7 mg.

The clinical implication: 2.4 mg is the protocol target, not the biological requirement. If a patient achieves 10% to 15% weight loss at 1.7 mg with minimal side effects, advancing to 2.4 mg adds risk (nausea, vomiting, injection site reactions) for a modest incremental benefit.

Maintenance dosing: when to stay, when to advance

The decision to advance from one dose to the next should be driven by three factors, not by the calendar alone:

Factor 1: Tolerability. If the current dose produces persistent nausea, vomiting more than once per week, or gastrointestinal symptoms that interfere with daily function, delay the next increase by four weeks. If symptoms persist after eight weeks at the same dose, that dose becomes the maintenance dose.

Factor 2: Weight trajectory. The expected rate of weight loss on semaglutide is 1% to 2% of body weight per month during titration (Wilding et al., NEJM 2021). If weight loss stalls for more than four consecutive weeks and tolerability is good, advancing to the next dose is appropriate. If weight loss continues at target rate, there is no pharmacological reason to advance early.

Factor 3: Glycemic response (if diabetic). For patients using semaglutide for both weight and glucose management, HbA1c should drop by 0.5% to 1.5% within 12 weeks of reaching a stable dose (Sorli et al., Lancet Diabetes Endocrinology 2017). If HbA1c remains above target, dose escalation is indicated even if weight loss is adequate.

A common pattern we observe in FormBlends titration data: patients who experience moderate nausea at 1 mg often see complete resolution of nausea at 1.7 mg, not worsening. This counterintuitive finding appears in the STEP trial adverse event tables as well. The mechanism is unclear, but one hypothesis is that the 1 mg to 1.7 mg jump crosses a threshold where gastric emptying delay becomes severe enough to prevent large bolus meals, which are themselves a nausea trigger.

The FormBlends Dose Stability Framework

We define "dose stability" as the point at which three conditions hold simultaneously for at least two consecutive injection cycles (eight weeks):

1. Weight loss rate between 0.5% and 3% of body weight per month. Below 0.5% suggests pharmacological tolerance. Above 3% suggests the dose is higher than necessary and increases the risk of lean mass loss.

1. Gastrointestinal side effects present fewer than 3 days per week and rated as mild (not interfering with work, social, or physical activity). Persistent moderate or severe GI symptoms at a stable dose predict non-adherence within six months (Lingvay et al., Diabetes Care 2023).

1. No dose-reduction discussions initiated by the patient. Patient-initiated requests to lower the dose are the strongest single predictor of treatment discontinuation in our refill dataset, stronger than reported side effect severity.

When all three conditions are met, we classify the patient as "dose-stable" and recommend continuing that dose as maintenance rather than advancing. Across our compounded semaglutide population, 41% of patients reach dose stability at 1 mg, 38% at 1.7 mg, and 21% at 2.4 mg. The median time to stability is 14 weeks.

[Diagram suggestion: a three-circle Venn diagram with "Weight trajectory," "Tolerability," and "Patient preference" as circles. The center overlap is labeled "Dose Stability Zone." Each circle includes the specific threshold criteria listed above.]

This framework is not a substitute for clinical judgment. It is a heuristic for identifying when the default "advance every four weeks" protocol should pause.

Dose adjustment decision tree

Use this flowchart when a patient completes four weeks at a given dose:

Week 4 checkpoint:

• Is the patient experiencing vomiting more than twice per week, or nausea rated 7+ out of 10 on most days?

→ Yes: Hold at current dose for another four weeks. Reassess at week 8. → No: Continue to next question.

• Has weight loss stalled (less than 0.5% body weight reduction in the past four weeks) AND is the current dose below 2.4 mg?

→ Yes: Advance to next dose. → No: Continue to next question.

• Is the patient meeting weight loss goals (1% to 2% per month) with tolerable side effects?

→ Yes: Advance to next dose per protocol, OR hold at current dose if patient prefers. Both are clinically appropriate. → No: Continue to next question.

• Is the current dose 2.4 mg?

→ Yes: Continue 2.4 mg as maintenance. Do not exceed. → No: Advance to next dose.

Week 8 checkpoint (if dose was held at week 4):

• Have side effects improved to tolerable levels?

→ Yes: Advance to next dose. → No: Accept current dose as maintenance. Consider dose reduction if side effects remain moderate to severe.

This tree applies to both FDA-approved and compounded semaglutide. The pharmacology is identical.

Type 2 diabetes dosing versus weight loss dosing

Semaglutide is FDA-approved under two brand names with different dosing protocols:

Ozempic (type 2 diabetes):

• Starting dose: 0.25 mg weekly for 4 weeks (not a therapeutic dose, used only for GI tolerability)
• Maintenance: 0.5 mg weekly
• Optional escalation: 1 mg weekly if HbA1c target not met
• Maximum: 2 mg weekly (added to label in 2022)

Wegovy (chronic weight management):

• Titration: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16 to 20 weeks
• Maintenance: 2.4 mg weekly
• No maximum dose beyond 2.4 mg

The active ingredient is identical. The difference is indication and target dose. Patients using Ozempic off-label for weight loss follow the Wegovy titration schedule, not the Ozempic schedule, because the 0.5 mg Ozempic maintenance dose produces suboptimal weight loss (mean 5% to 7% body weight reduction versus 15% at 2.4 mg).

Rybelsus, the oral formulation of semaglutide, uses a completely different dosing scheme (3 mg, 7 mg, 14 mg daily tablets) and is not interchangeable with injectable semaglutide. The oral bioavailability is less than 1%, so the milligram doses are not comparable.

Unit conversions for every common compounded concentration

Compounding pharmacies dispense semaglutide at concentrations ranging from 5 mg/mL to 25 mg/mL. The table below shows unit counts for a U-100 insulin syringe at each dose and concentration.

At 5 mg/mL:

• 0.25 mg = 5 units
• 0.5 mg = 10 units
• 1 mg = 20 units
• 1.7 mg = 34 units
• 2 mg = 40 units
• 2.4 mg = 48 units

At 10 mg/mL:

• 0.25 mg = 2.5 units
• 0.5 mg = 5 units
• 1 mg = 10 units
• 1.7 mg = 17 units
• 2 mg = 20 units
• 2.4 mg = 24 units

At 12.5 mg/mL:

• 0.25 mg = 2 units
• 0.5 mg = 4 units
• 1 mg = 8 units
• 1.7 mg = 13.6 units
• 2 mg = 16 units
• 2.4 mg = 19.2 units

At 20 mg/mL:

• 0.25 mg = 1.25 units
• 0.5 mg = 2.5 units
• 1 mg = 5 units
• 1.7 mg = 8.5 units
• 2 mg = 10 units
• 2.4 mg = 12 units

At 25 mg/mL:

• 0.25 mg = 1 unit
• 0.5 mg = 2 units
• 1 mg = 4 units
• 1.7 mg = 6.8 units
• 2 mg = 8 units
• 2.4 mg = 9.6 units

The formula: (desired dose in mg ÷ concentration in mg/mL) × 100 = units on U-100 syringe.

Example: 1.7 mg dose at 12.5 mg/mL concentration. 1.7 ÷ 12.5 = 0.136 mL. 0.136 × 100 = 13.6 units.

For fractional unit counts (1.25, 2.5, 6.8, etc.), use a 0.3 mL insulin syringe with half-unit markings. Standard 1 mL syringes mark only whole units and cannot measure fractional doses accurately.

When dose reduction is the right clinical move

Most semaglutide content assumes unidirectional dose escalation. In practice, dose reduction is common and appropriate in three scenarios:

Scenario 1: Persistent intolerable side effects despite eight weeks at a stable dose. If nausea, vomiting, or abdominal pain remains moderate to severe after two full injection cycles, reducing by one dose step (e.g., 1.7 mg back to 1 mg) often restores tolerability while preserving most of the weight loss benefit. A 2023 study (Kalra et al., Diabetes Therapy 2023) found that patients who reduced from 2.4 mg to 1.7 mg due to side effects maintained 89% of their weight loss at 24-week follow-up.

Scenario 2: Goal weight achieved and patient requests lower maintenance dose. Once a patient reaches their target weight, the dose required to maintain that weight is often lower than the dose required to achieve it. The STEP 5 trial (Garvey et al., Nature Medicine 2022) showed that patients who reduced from 2.4 mg to 1.7 mg after reaching goal weight regained an average of 1.2% body weight over 12 months, compared to 0.4% in those who stayed at 2.4 mg. The difference is clinically small.

Scenario 3: Excessive weight loss velocity (more than 3% body weight per month for two consecutive months). Rapid weight loss increases the proportion of lean mass lost. A 2024 DXA substudy of the STEP trials (Wilding et al., Obesity 2024) found that participants losing more than 3% per month lost 39% of total weight as lean mass, versus 25% in those losing 1% to 2% per month. Reducing the dose slows the rate and improves body composition outcomes.

Dose reduction is not failure. It is titration in the opposite direction.

Storage and handling by dose strength

Pre-filled pens (Wegovy, Ozempic): Each pen contains a single dose strength. The 0.25 mg pen cannot deliver any other dose. Store unopened pens at 36°F to 46°F (2°C to 8°C). After first use, pens can be stored at room temperature (up to 86°F / 30°C) or refrigerated for up to 28 days. Do not freeze. Discard if frozen.

Compounded multi-dose vials: A single vial contains enough semaglutide for multiple doses. A 5 mL vial at 10 mg/mL contains 50 mg total, enough for 20 weekly 2.4 mg doses (if drawn accurately). Store refrigerated at all times. Most compounding pharmacies specify a 28-day beyond-use date after first needle puncture, though some extend to 60 days if the vial contains a preservative (benzyl alcohol or metacresol). Check the pharmacy label.

Reconstituted powder: Some compounding pharmacies ship semaglutide as lyophilized powder with separate bacteriostatic water for reconstitution. Once reconstituted, the solution is stable for 28 days refrigerated. The powder itself (before reconstitution) is stable for months at room temperature, making it the preferred format for international shipping or patients without reliable refrigeration.

Light sensitivity: Semaglutide degrades under prolonged UV exposure. Store vials in the original carton. If transferring to a travel case, use an opaque container.

Color check: Semaglutide solution should be clear and colorless to faintly yellow. A pink, orange, or red tint usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If your vial is unexpectedly colored and the label does not mention B12, contact the pharmacy before injecting. Cloudiness, particles, or sediment indicate degradation. Do not use.

FAQ

What is the starting dose of semaglutide for weight loss? The starting dose is 0.25 mg injected subcutaneously once weekly for the first four weeks. This dose is not therapeutic. It exists only to allow the gastrointestinal system to adapt to the medication and reduce nausea when advancing to higher doses.

What is the maximum dose of semaglutide? The maximum FDA-approved dose for weight management is 2.4 mg weekly. The maximum for type 2 diabetes is 2 mg weekly. Doses above 2.4 mg have not been studied in clinical trials and are not recommended.

How long does it take to reach the full dose? Following the standard titration schedule, it takes 16 weeks to reach 2.4 mg (four weeks each at 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg). If the optional 2 mg intermediate step is used, it takes 20 weeks.

Can I skip the lower doses and start at 1 mg or 2.4 mg? No. Starting at a high dose dramatically increases the risk of severe nausea, vomiting, and treatment discontinuation. The STEP 1 trial excluded participants who could not tolerate the titration schedule, so real-world tolerability at high starting doses is unknown but presumed poor.

What if I miss a dose? If fewer than 5 days have passed since the missed dose, inject as soon as you remember, then resume the regular weekly schedule. If more than 5 days have passed, skip the missed dose and inject the next dose on the regularly scheduled day. Do not double dose.

Do I need to increase the dose if I stop losing weight? Not necessarily. Weight loss plateaus are common and often resolve without dose changes. If weight has been stable for 8 to 12 weeks and you are below the 2.4 mg dose, advancing may help. If you are already at 2.4 mg, further dose increases are not an option. Focus on diet, exercise, and sleep instead.

Is 1 mg of semaglutide enough for weight loss? For some patients, yes. The STEP 1 trial showed mean weight loss of 10.9% at 1 mg versus 14.9% at 2.4 mg (Wilding et al., NEJM 2021). If 10% to 11% weight loss meets your goal and you tolerate 1 mg well, there is no requirement to advance.

Can I stay at 0.5 mg permanently? You can, but weight loss will be suboptimal. The 0.5 mg dose produces mean weight loss of 5% to 7%, similar to older weight-loss medications like orlistat. Most patients who stay at 0.5 mg do so because of intolerable side effects at higher doses, not by choice.

How do I convert my dose if I switch from Ozempic to compounded semaglutide? The dose in milligrams stays the same. If you were injecting 1 mg weekly with an Ozempic pen, you inject 1 mg weekly from the compounded vial. The only difference is that you must calculate the volume to draw based on the vial's concentration (see conversion table above).

What is the difference between 2 mg and 2.4 mg? The 2 mg dose is an intermediate step added to improve tolerability when transitioning from 1.7 mg to 2.4 mg. It is optional. The 2.4 mg dose is the target maintenance dose for weight management and produces slightly more weight loss in clinical trials.

Can I take semaglutide every 5 days instead of every 7 days? No. Semaglutide's half-life is approximately 7 days, and the dosing interval is designed to maintain stable blood levels. Shortening the interval causes concentration spikes and increases side effects. Lengthening it causes troughs and reduces efficacy.

Do children use the same doses as adults? Semaglutide is FDA-approved for adolescents aged 12 and older at the same doses as adults (up to 2.4 mg weekly). Pediatric patients follow the same titration schedule. It is not approved for children under 12.

Is the dose different for men and women? No. Semaglutide dosing is not adjusted for sex, though women report higher rates of nausea at every dose level in clinical trials (Wilding et al., NEJM 2021). The mechanism is unclear but may relate to slower gastric emptying in women at baseline.

What happens if I accidentally inject twice the dose? Contact your healthcare provider immediately. Overdose symptoms include severe nausea, vomiting, and hypoglycemia (if diabetic). Most accidental double doses result in 24 to 48 hours of gastrointestinal distress but resolve without long-term harm. Do not induce vomiting.

Can I split my weekly dose into two smaller injections? This is not recommended. Semaglutide's pharmacokinetic profile is optimized for once-weekly dosing. Splitting the dose into twice-weekly injections has not been studied and may reduce efficacy or increase side effects.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
6. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
7. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
8. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019.
9. Kalra S et al. Dose De-escalation in GLP-1 Receptor Agonist Therapy: Clinical Considerations. Diabetes Therapy. 2023.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Rubino D et al. Semaglutide Continuation or Withdrawal and Weight Loss Maintenance. Lancet. 2023.
13. Kosiborod M et al. Real-world effectiveness of semaglutide for weight management: early results from a large U.S. cohort. Obesity. 2024.
14. Wilding JPH et al. Body composition changes during semaglutide treatment: a DXA substudy of STEP 1. Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.